Back to Rankings

IMVT

ImmunovantC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The post-print bull case is that the market is willing to look through the widened loss because IMVT-1402 produced strong open-label D2T RA activity, no new safety signals, and enough cash to fund announced indications through a potential GD launch. Stifel was reported to reiterate Buy with a $49 target after the release, reinforcing that some analysts see the data as supporting a higher valuation.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.5.
What can break
Batoclimab discontinuation leaves IMVT-1402 as the dominant strategic driver, increasing concentration risk.
Momentum
90
Value
41
Sentiment
36
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $37.00 · Bull $52.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-23 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $46.47
Why
Momentum90 · Δ7d +4.5
Value41 · Δ7d -0.1
Sentiment36 · Δ7d -3.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
+4.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
36
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.7
Δ21d
-4.3
Why this grade

Composite grade C. Momentum 89.7 / Value 41.1 / Sentiment 35.6

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$8.27B
Beta
0.54
Shares Out
205.31M
P/E (TTM) · Derived
-14.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.87
Rev YoY
-
EPS YoY
+13.7%
Gross Margin
-
Op Margin
-
Net Debt
-$902.04M
Current Ratio
9.09
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology